Clinical Trial Update: Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of AVE0005 (aflibercept, VEGF trap) in chemoresistant advanced ovarian cancer has completed with results posted in 2012. Sponsor is Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: Sanofi | Conditions: Neoplasms, Cancer of the Ovary | Phase 2 | Status: COMPLETED | Results posted: 2012-10-18